
Opinion|Videos|November 13, 2026
LITESPARK-022: Immature Overall Survival Data and the Added-Toxicity Trade-Off
Desai and Kydd discuss LITESPARK-022's immature overall survival signal (HR 0.78) and the 22% increase in grade 3+ adverse events with belzutifan.
Advertisement
Advertisement
Related to this article

Adjuvant cretostimogene reduced recurrence risk by 68% vs surveillance in intermediate-risk and high-grade Ta NMIBC in the phase 3 PIVOT-006 trial.

The FDA has approved pertuzumab-qcay, a biosimilar of the reference product Perjeta, in HER2-positive breast cancer, based on a data package that showed no meaningful differences in quality, safety, efficacy, or immunogenicity.

Ralph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.

A complete response letter was given to ivonescimab for patients with previously treated EGFR-mutated NSCLC.

Matthew Karr, DO, highlights advances in the CLL paradigm, current goals in researching CNS lymphoma, and other future directions in hematology/oncology.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Provides CRL to Ivonescimab/Chemotherapy for Pretreated EGFR+ NSCLC
2
Matching Neoadjuvant Therapy to Tumor Genomics in High-Risk Prostate Cancer
3
Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific Antibodies
4
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
5
